The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2017 | Ibrutinib and ublituximab – a promising combination regimen for treating CLL?
Susan O’Brien, MD from the University of California, Irvine, CA discusses the potential of ibrutinib in combination with a new anti-CD20 monoclonal antibody, ublituximab, in treating chronic lymphocytic leukemia at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL. She points out that although this combinatorial regimen produced impressive results in patients in a randomised clinical trial (NCT02301156), it is currently questionable whether this regimen will be effective in the long-term run.
